autoimmune diseases
Conditions
Interventions
Sponsors
The Second Affiliated Hospital of Guangzhou Medical University
Eligibility
Sex/Gender
All
Age
6 Years to 65 Years
Inclusion criteria
Inclusion criteria: 1 "Psoriasis" Inclusion Criteria: 1) Voluntary signing of informed consent; 2) Aged 6-65 years (including 6, 65 years old), gender is not limited; 3) Clinical and pathological diagnosis of patients with psoriasis vulgaris (diagnostic criteria refer to Zhao Jie, "Chinese Clinical Dermatology"): rash manifested as erythema, scales, membrane phenomenon, punctiform hemorrhage and main body extension Characteristics of symmetry distribution; punctate, small spherical, hairpin-like, ring-shaped blood vessels under a bright red background, diffusely distributed white scales; 4) PASI score = 12 points for mild to moderate psoriasis. 2 "Rheumatoid Arthritis" Inclusion Criteria: 1) Diagnosed as adult-onset RA with the American Association of Rheumatology 1987 RA classification criteria, and erythrocyte sedimentation rate or C-reactive protein = 1.4 times the upper limit of the normal range. 2) The drug treatment was not effective, and the DAS28 score was >2.6 points or more, and the drug treatment program did not change during the probiotic intervention. 3) Aged 18 to 65 years. 4) Voluntary signing of informed consent. 3 "Allergic Rhinitis" Inclusion Criteria: 1) Aged 18 to 60 years, both men and women. 2) In line with the clinical diagnostic criteria for perennial moderate to severe allergic rhinitis, the total symptom is divided into 6 or more, affecting the quality of life, and the course of disease is more than 2 years. 3) Allergen skin test or sIgE test positive, allergen nasal mucosa positive. 4) Willing to sign informed consent.
Exclusion criteria
Exclusion criteria: 1 "Psoriasis" Exclusion Criteria: 1) Taking hormones or immunosuppressive drugs within one month; 2) Received other clinical trials within one month; 3) Women who are pregnant or breast-feeding, or women of childbearing age who cannot take oral contraceptives during the trial; 4) Patients with other important organ function impairments or diseases such as heart, lung and kidney. 2 "Rheumatoid Arthritis" Exclusion Criteria: 1) Pregnant women, lactating women, or women of childbearing age who take oral contraceptives during the trial; 2) Received other clinical trials within one month; 3) The investigators confirmed that the subjects had current or recent severe, progressive, and uncontrolled heart, lung, liver, kidney and other vital organs and blood, endocrine system lesions and medical history; 4) Patients who are infected with herpes zoster or HIV infection at screening or who are at high risk of infection. 3 "Allergic Rhinitis" Exclusion Criteria: 1) Pregnant women, lactating women, or women of childbearing age who take oral contraceptives during the trial; 2) Patients with other diseases requiring long-term treatment with hormones and immunosuppressive drugs; 3) Patients with other important organ dysfunction or diseases such as heart, lung and kidney; 4) Hepatitis B, syphilis, AIDS and other chronic infections; 5) Received other clinical trials within one month.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| PASI Score;DAS28;Nasal symptoms VAS score;Drug reduction rate; | — |
Secondary
| Measure | Time frame |
|---|---|
| weight;CD3+CD4+;CD3+;CD3+CD8+;CD19+B;NK;ESR;CRP; | — |
Countries
China
Contacts
Public ContactDeng Yuhong
Outcome results
None listed